Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Open accessThe DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.
Abstract
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 The slope of the mean pulmonary arterial pressure (mPAP)–cardiac output (CO) relationship is different in normal control versus pulmonary arterial hypertension (PAH) subjects. Reproduced and modified from [26] with permission.](https://figures.cochat.ai/paper-figures/36e057af8c4544adb1c352faf9a06761/haemodynamic-definitions-and-updated-clinical-classification-of-pulmonary-figure-1.jpg)
![FIGURE 2 Knowledge of the mean pulmonary arterial pressure (mPAP)–cardiac output (CO) relationship does not allow distinction between left heart disease (LHD) and pulmonary vascular disease (PVD) patients; knowledge of exercise pulmonary arterial wedge pressure is also required. TPR: total pulmonary resistance; WU: Wood Units. Reproduced from [29] with permission.](https://figures.cochat.ai/paper-figures/8474dfd09d604465902cbdde1d1fd85a/haemodynamic-definitions-and-updated-clinical-classification-of-pulmonary-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pulmonary hypertension can also occur in the context of congenital heart disease.(301)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [301]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationDe Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citationClinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Self-citationDefinitions and Diagnosis of Pulmonary Hypertension
Hoeper, M. M., Bogaard, H. J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T., Torres, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.032 · Cited by 1,766
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Self-citation
Research works printed but not linked: 2
- Reeves J , Dempsey J , Grover R . Pulmonary circulation during exercise. In: Weir EK , Reeves JT , eds. Pulmonary Vascular Physiology and Physiopathology. New York, Marcel Dekker, 1989; pp. 107–133. · doi:10.1201/9781003573739-5
- Tamura Y , Furukawa A , Li T , et al. Severe pulmonary arterial hypertension in patients treated by Chinese herb nature indigo: Qing-Dai. Poster presentation at the 6th World Symposium on Pulmonary Hypertension, Nice, 2018; A108.
Cited by
Items 501–600 of 1,004
Morrisroe, K., Hansen, D., Stevens, W., Sahhar, J., Ngian, G., Hill, C. L., Roddy, J., Walker, J. G., Proudman, S., & Nikpour, M. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02790-1 · Cited by 35
miRNAs orchestration of cardiovascular diseases – Particular emphasis on diagnosis, and progression
Elsakka, E. G. E., Abulsoud, A. I., El‐Mahdy, H. A., Ismail, A., Elballal, M. S., Mageed, S. S. A., Khidr, E. G., Mohammed, O. A., Sarhan, O. M., Elkhawaga, S. Y., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154613 · Cited by 35
Kularatne, M., Gerges, C., Jevnikar, M., Humbert, M. J. C., & Montani, D. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11030078 · Cited by 35
Self-citationPulmonary Hypertension in COPD: A Case Study and Review of the Literature
Cassady, S. J., & Reed, R. M. (2019) · Medicina · doi:10.3390/medicina55080432 · Cited by 35
Waller, L., Krüger, K., Conrad, K. D., Weiß, A., & Alack, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061689 · Cited by 35
Ullah, W., Minalyan, A., Saleem, S., Nadeem, N., Abdullah, H. M. A., Abdalla, A., Chan, V., Saeed, R., Khan, M., Collins, S. D., et al. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100568 · Cited by 35
Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension
Anand, V., Vallabhajosyula, S., Cheungpasitporn, W., Frantz, R. P., Cajigas, H. R., Strand, J. J., & DuBrock, H. M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.079 · Cited by 35
Pediatric Pulmonary Arterial Hypertension
Frank, B. S., & Ivy, D. D. (2020) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2020.06.005 · Cited by 35
Lago‐Docampo, M., Tenorio, J. A., Hernández‐González, I., Pérez‐Olivares, C., Subías, P. E., Pousada, G., Baloira, A., Arenas, M., Lapunzina, P. D., & Valverde, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-72089-1 · Cited by 35
Decker, P., Moulinet, T., López, B., Dubucquoi, S., Bonnotte, B., Lakomy, D., Revuz, S., Luc, A., Bittencourt, M. D. C., HACHULLA, E., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.020 · Cited by 35
ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension
Montagnoli, T. L., da Silva, J. S., Sudo, S. Z., Santos, A. D., Gomide, G. F., de Sá, M. P. L., & Zapata‐Sudo, G. (2021) · Cells · doi:10.3390/cells10071648 · Cited by 35
Prisco, S. Z., Hartweck, L. M., Rose, L., Lima, P. D. A., Thenappan, T., Archer, S. L., & Prins, K. W. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008574 · Cited by 35
Hannemann, J., & Böger, R. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.835481 · Cited by 35
Pugliese, N. R., Mazzola, M., Madonna, R., Gargani, L., Biase, N. D., Dini, F. L., Taddei, S., Caterina, R. D., & Masi, S. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.106978 · Cited by 35
Contribution of fatty acid oxidation to the pathogenesis of pulmonary hypertension
Lee, M. H., Sanders, L., Kumar, R., Hernández-Saavedra, D., Yun, X., Ford, J. A., Perez, M. J., Mickael, C. S., Gandjeva, A., Koyanagi, D. E., et al. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00039.2022 · Cited by 35
Saygın, D., & Domsic, R. T. (2019) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s228234 · Cited by 35
Morrisroe, K., Hansen, D., Stevens, W., Ross, L., Sahhar, J., Ngian, G., Hill, C. L., Host, L., Walker, J. G., Proudman, S., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead491 · Cited by 34
Cardiovascular disease assessment and management in liver transplantation
Harinstein, M. E., Gandolfo, C. M., Gruttadauria, S., Accardo, C., Crespo, G., VanWagner, L. B., & Humar, A. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae502 · Cited by 34
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia
Nakamura, K., Akagi, S., Ejiri, K., Taya, S., Saito, Y., Kuroda, K., Takaya, Y., Toh, N., Nakayama, R., Katanosaka, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020835 · Cited by 34
The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension
Stadler, S., Mergenthaler, N., & Lange, T. J. (2019) · Pulmonary Circulation · doi:10.1177/2045894019894531 · Cited by 34
Atsukawa, M., Tsubota, A., Hatano, M., Kondo, C., Shioda, K., Ohno, H., Kawano, T., Hayama, K., Arai, T., Nakagawa‐Iwashita, A., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13560 · Cited by 34
NDUFA4L2 in smooth muscle promotes vascular remodeling in hypoxic pulmonary arterial hypertension
Liu, Y., Nie, X., Zhu, J., Wang, T., Li, Y., Wang, Q., & Sun, Z. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16193 · Cited by 34
Wright, S. P., Dawkins, T. G., Eves, N. D., Shave, R., Tedford, R. J., & Mak, S. S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00720.2020 · Cited by 34
Congenital Heart Disease-Associated Pulmonary Hypertension
Rosenzweig, E. B., & Krishnan, U. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.11.005 · Cited by 34
App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study
Salvi, D., Poffley, E., Tarassenko, L., & Orchard, E. (2021) · JMIR mhealth and uhealth · doi:10.2196/22748 · Cited by 34
Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension
Sherman, A. E., & Saggar, R. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.015 · Cited by 34
Montani, D., Thoré, P., Mignard, X., Jaïs, X., Boucly, A., Jevnikar, M., Seferian, A., Jutant, E., Cottin, V., Fadel, É., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202210-1941oc · Cited by 34
Self-citationVagus nerve stimulation for cardiovascular diseases: Is there light at the end of the tunnel?
Zafeiropoulos, S., Ahmed, U., Bikou, A., Mughrabi, I. T., Stavrakis, S., & Zanos, S. P. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.07.003 · Cited by 34
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Mecoli, C. A., Adler, B. L., Yang, Q., Hummers, L. K., Rosen, A., Casciola-Rosen, L. A., & Shah, A. A. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41493 · Cited by 34
Györfi, A., Filla, T., Polzin, A., Taşçılar, K., Buch, M. H., Tröbs, M., Matei, A., Airó, P., Balbir‐Gurman, A., Kuwert, F., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036730 · Cited by 33
Cardiovascular complications of systemic sclerosis: What to look for
Mani, P., Gonzalez, D., Chatterjee, S., & Faulx, M. D. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18109 · Cited by 33
Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension
Boucly, A., Morélot‐Panzini, C., Garcia, G., Weatherald, J. C., Jaïs, X., Savale, L., Montani, D., Humbert, M. J. C., Similowski, T., Sitbon, O., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02108-2018 · Cited by 33
Self-citationBisserier, M., Janoštiak, R., Lezoualc’h, F., & Hadri, L. (2020) · Vascular Biology · doi:10.1530/vb-19-0030 · Cited by 33
Luo, J., Li, H., Liu, Z., Li, C., Wang, R., Fang, J., Lu, S., Guo, J., Zhu, X., & Wang, X. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00740-x · Cited by 33
Becker, K., Uebing, A. S., & Hansen, J. H. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-431 · Cited by 33
Management of chronic respiratory complications in children and adolescents with sickle cell disease
Arigliani, M., & Gupta, A. (2020) · European Respiratory Review · doi:10.1183/16000617.0054-2020 · Cited by 33
Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
Haarman, M. G., Lévy, M., Roofthooft, M. T. R., Douwes, J. M., Vissia-Kazemier, T. R., Szézépanski, I., Berger, R. M. F., & Bonnet, D. (2020) · European Respiratory Journal · doi:10.1183/13993003.01120-2020 · Cited by 33
Ong, M., Klann, J. G., Lin, K. J., Maron, B. A., Murphy, S. N., Natter, M. D., & Mandl, K. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016648 · Cited by 33
Cardiac Magnetic Resonance in Pulmonary Hypertension—an Update
Alabed, S., Garg, P., Johns, C., Alandejani, F., Shahin, Y., Dwivedi, K., Zafar, H., Wild, J. M., Kiely, D. G., & Swift, A. J. (2020) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-020-09550-2 · Cited by 33
Jutiviboonsuk, A., Salang, L., Eamudomkarn, N., Mahakkanukrauh, A., Suwannaroj, S., & Foocharoen, C. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05522-5 · Cited by 33
Yi, D., Liu, B., Wang, T., Liao, Q., Zhu, M. M., Zhao, Y., & Dai, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063182 · Cited by 33
Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension
Zolty, R. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s236743 · Cited by 33
Evaluation of Pulmonary Hypertension Using 4D Flow MRI
Cerne, J. W., Pathrose, A., Gordon, D. Z., Sarnari, R., Veer, M., Blaisdell, J. A., Allen, B. D., Avery, R. J., Markl, M., Ragin, A. B., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27967 · Cited by 33
Masson, B., Montani, D., Humbert, M. J. C., Capuano, V., & Antigny, F. (2021) · Biomolecules · doi:10.3390/biom11121781 · Cited by 33
Self-citationPulmonary arterial hypertension
Luna‐López, R., Martín, A. R., & Subías, P. E. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.05.010 · Cited by 33
Chen, T., Su, S., Yang, Z., Zhang, D., Li, Z., & Lu, D. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115572 · Cited by 33
Hopper, R. K., Abman, S. H., Elia, E. G., Avitabile, C. M., Yung, D., Mullen, M. P., Austin, E. D., Bates, A., Handler, S. S., Feinstein, J. A., et al. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.08.027 · Cited by 33
Focus on long non-coding RNA MALAT1: Insights into acute and chronic lung diseases
Lai, X., Zhong, J., Zhang, A., Zhang, B., Zhu, T., & Liao, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1003964 · Cited by 33
Mitochondrial Dysfunction in Pulmonary Hypertension
Ryanto, G. R. T., Suraya, R., & Nagano, T. (2023) · Antioxidants · doi:10.3390/antiox12020372 · Cited by 33
Transcriptional profiles of pulmonary artery endothelial cells in pulmonary hypertension
Singh, N., Eickhoff, C., García-Agúndez, A., Bertone, P., Paudel, S. S., Tambe, D. T., Litzky, L. A., Cox, K., Klinger, J. R., Monaghan, S. F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48077-6 · Cited by 33
Kraft, M., Büscher, A., Wiedmann, F., L’hoste, Y., Haefeli, W. E., Frey, N., Katus, H. A., & Schmidt, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638445 · Cited by 33
Revising the hemodynamic criteria for pulmonary hypertension: A perspective from China
Xiong, C., & Yang, B. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0023 · Cited by 32
Obstructive Sleep Apnea and Pulmonary Hypertension: A Chicken-and-Egg Relationship
Balcan, B., Akdeniz, B., Peker, Y., & Collaborators, T. T. C. T. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102961 · Cited by 32
Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease
Neubert, L., Borchert, P., Stark, H., Hoefer, A., Vogel‐Claussen, J., Warnecke, G., Eubel, H., Künzler, P., Kreipe, H.-H., Hoeper, M. M., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.03.008 · Cited by 32
Dotan, Y., Stewart, J., Gangemi, A. J., Wang, H., Aneja, A., Chakraborty, B., Dass, C. A., Zhao, H., Marchetti, N. T., D’Alonzo, G. E., et al. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000532 · Cited by 32
Meinel, K., Köestenberger, M., Sallmon, H., Hansmann, G., & Pieles, G. E. (2020) · Diagnostics · doi:10.3390/diagnostics11010049 · Cited by 32
Exposición crónica a la altura. Características clínicas y diagnóstico
Santos-Martínez, L. E., Tejada, R. A. G., Murillo-Jauregui, C. X., Hoyos, R., Poyares-Jardim, C. V., & Orozco‐Levi, M. (2021) · Archivos de cardiología de México · doi:10.24875/acm.20000447 · Cited by 32
Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future
Mingora, C. M., & Flume, P. A. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.017 · Cited by 32
Ohuchi, H., Kawata, M., Uemura, H., Akagi, T., Yao, A., Senzaki, H., Kasahara, S., Ichikawa, H., Motoki, H., Syoda, M., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0134 · Cited by 32
Harder, E. M., Divo, M. J., Washko, G. R., Leopold, J. A., Rahaghi, F. N., & Waxman, A. B. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202306-1072oc · Cited by 32
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Säleby, J., Bouzina, H., Ahmed, S., Lundgren, J., & Rådegran, G. (2019) · ERJ Open Research · doi:10.1183/23120541.00037-2019 · Cited by 32
Richter, M. J., Fortuni, F., Wiegand, M. A., Dalmer, A., Vanderpool, R. R., Ghofrani, H. A., Naeije, R., Roller, F. C., Seeger, W., Sommer, N., et al. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-019-01763-x · Cited by 32
Association Between Systemic and Pulmonary Vascular Dysfunction in COPD
Piccari, L., del Pozo, R., Blanco, I., García-Lucio, J., Torralba, Y., Tura-Ceide, O., Moisés, J., Sitges, M., Peinado, V. I., & Barberà, J. A. (2020) · International Journal of COPD · doi:10.2147/copd.s257679 · Cited by 32
Proposed new pulmonary hypertension definition: is 4 mm(Hg) worth re-writing medical textbooks?
Gibbs, J. S. R., & Torbicki, A. (2019) · European Respiratory Journal · doi:10.1183/13993003.00197-2019 · Cited by 32
Zhao, S., Liu, J., Wu, Q., & Zhou, X. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1268646 · Cited by 31
Anti-remodeling therapies in pulmonary arterial hypertension
Boucherat, O., Bonnet, S., Provencher, S., & Potus, F. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.05.004 · Cited by 31
The Search for Disease-Modifying Therapies in Pulmonary Hypertension
Woodcock, C.-S. C., & Chan, S. Y. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419829172 · Cited by 31
Ventetuolo, C. E., Aliotta, J. M., Braza, J., Chichger, H., Dooner, M. S., McGuirl, D., Mullin, C. J., Newton, J., Pereira, M. G., Princiotto, A. M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01313-2019 · Cited by 31
Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?
Alfaro, T. M., & Cordeiro, C. R. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620910092 · Cited by 31
DesJardin, J. T., Kolaitis, N. A., Kime, N. A., Kronmal, R. A., Benza, R. L., Elwing, J., Lammi, M. R., McConnell, J. W., Presberg, K. W., Sager, J. S., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.05.005 · Cited by 31
Nuche, J., de la Cal, T. S., López-Guarch, C. J., López‐Medrano, F., Delgado, C. P.-O., Arribas, F., Delgado, J. F., Ibáñez, B., Oliver, E., & Subías, P. E. (2020) · Diagnostics · doi:10.3390/diagnostics10080548 · Cited by 31
Pulmonary Vascular Disease and Cardiopulmonary Exercise Testing
Laveneziana, P., & Weatherald, J. C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00964 · Cited by 31
Wang, T., Hou, J., Xiao, W., Zhang, Y., Zhou, L., Li, Y., Yin, X., Chen, X., & Hu, Y. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1804407 · Cited by 31
Singh, I., Oliveira, R. K. F., Heerdt, P. M., Pari, R., Systrom, D. M., & Waxman, A. B. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.12.028 · Cited by 31
Brown, Z., Proudman, S., Morrisroe, K., Stevens, W., Hansen, D., & Nikpour, M. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.03.011 · Cited by 31
Jha, M., Wang, M., Steele, R. J., Baron, M. G., Fritzler, M. J., & Hudson, M. (2021) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983211040608 · Cited by 31
Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension
Mathew, R. (2021) · Medical Sciences · doi:10.3390/medsci9040058 · Cited by 31
Bartolo, M. A., Qureshi, M. U., Colebank, M. J., Chesler, N. C., & Olufsen, M. S. (2022) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-021-01538-1 · Cited by 31
Clinical Application of 4D Flow MR Imaging to Pulmonary Hypertension
Ota, H., Kamada, H., Higuchi, S., & Takase, K. (2022) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2021-0111 · Cited by 31
AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension
Flores, K., Siqués, P., Brito, J., & Arribas, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116205 · Cited by 31
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials
Ventetuolo, C. E., Moutchia, J., Baird, G. L., Appleby, D. H., McClelland, R. L., Minhas, J., Min, J., Holmes, J. H., Urbanowicz, R. J., Al‐Naamani, N., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202203-207oc · Cited by 31
Myronenko, O., Foris, V., Crnkovic, S., Olschewski, A., Rocha, S., Nicolls, M., & Olschewski, H. (2023) · European Respiratory Review · doi:10.1183/16000617.0173-2022 · Cited by 29
Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Nathan, S. D. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202212-2342ci · Cited by 31
Pulmonary hypertension and chronic lung disease: where are we headed?
Elia, D., Caminati, A., Zompatori, M., Cassandro, R., Lonati, C., Luisi, F., Pelosi, G., Provencher, S., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0065-2019 · Cited by 31
Antigny, F., Mercier, O. M., Humbert, M. J. C., & Sabourin, J. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.10.009 · Cited by 31
Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension
Truong, U. T., Meinel, K., Haddad, F., Köestenberger, M., Carlsen, J., Ivy, D. D., & Jone, P. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-272 · Cited by 31
Kocken, J. M. M., & Martins, P. A. D. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238901 · Cited by 31
Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation
Hiram, R., & Provencher, S. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.10.001 · Cited by 31
Jose, A., Shah, S. A., Anwar, N., Jones, C. R., Sherman, K. E., & Elwing, J. (2021) · Liver Transplantation · doi:10.1002/lt.26091 · Cited by 31
Tello, K., Yogeswaran, A., Majeed, R. W., Kiely, D. G., Lawrie, A., Brittain, E. L., Annis, J. S., Olschewski, H., Kovács, G., Hassoun, P. M., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.08.016 · Cited by 30
Self-citationShu, L., Zhang, R., Cai, Y.-H., Zhou, J., Yang, J., & Qi, L. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.10.002 · Cited by 30
Shavik, S. M., Tossas-Betancourt, C., Figueroa, C. A., Baek, S., & Lee, L. C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00002 · Cited by 30
Sonaglioni, A., Cassandro, R., Luisi, F., Ferrante, D., Nicolosi, G. L., Lombardo, M., Anzà, C., & Harari, S. A. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.10.009 · Cited by 30
Arvanitaki, A., Giannakoulas, G. A., Triantafyllidou, E., Feloukidis, C., Boutou, A., Garyfallos, A., Karvounis, H. I., & Dimitroulas, T. (2021) · Respiratory Research · doi:10.1186/s12931-021-01622-1 · Cited by 30
Liu, P., Huang, W. R. H., Ding, Y., Wu, J., Liang, Z., Huang, Z., Xie, W., & Kong, H. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s297500 · Cited by 30
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension
Heukels, P., Corneth, O. B. J., van Uden, D., van Hulst, J. A. C., van den Toorn, L. M., van den Bosch, A. E., Wijsenbeek, M. S., Boomars, K. A., Kool, M., & Hendriks, R. W. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215460 · Cited by 30
Zhang, H., He, H., Cui, Y., Yu, S., Li, S., Afedo, S. Y., Wang, Y., Bai, X., & He, J. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110140 · Cited by 30
Ruaro, B., Salton, F., Baratella, E., Confalonieri, P., Geri, P., Pozzan, R., Torregiani, C., Bulla, R., Confalonieri, M., Matucci‐Cerinic, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030616 · Cited by 30
Bier, E. A., Alenezi, F. A. M., Lu, J., Wang, Z., Mammarappallil, J. G., O’Sullivan-Murphy, B., Erkanli, A., Driehuys, B., & Rajagopal, S. (2022) · ERJ Open Research · doi:10.1183/23120541.00035-2022 · Cited by 30
EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension
Laggner, M., Oberndorfer, F., Golabi, B., Bauer, J., Zuckermann, A. O., Hacker, P., Lang, I. M., Skoro‐Sajer, N., Gerges, C., Taghavi, S., et al. (2022) · Biology · doi:10.3390/biology11050677 · Cited by 30
Metadata
- Authors
- Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R.
- Affiliations
- Université Paris-Sud (FR)
- The University of Sydney (AU)
- The Royal Free Hospital (GB)
- Mayo Clinic (US)
- Milpark Hospital (ZA)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801913
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351336
- OpenAlex
- W2904180601
- Cited by
- 3,813
- References
- 87
- Citations by year
- 2026: 208 · 2025: 356 · 2024: 480 · 2023: 541 · 2022: 716 · 2021: 711 · 2020: 558 · 2019: 225
- FWCI
- 282.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0033)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Keywords
- pulmonary hypertension, clinical classification, precapillary pulmonary hypertension, pulmonary arterial hypertension, pulmonary vascular resistance, mean pulmonary artery pressure, pulmonary vascular disease, pulmonary veno-occlusive disease, calcium channel blockers, right heart catheterization, reference values
- MeSH terms
- Consensus Statements as Topic, Heart Diseases, Hemodynamics, Humans, Hypertension, Pulmonary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.